1,796 material Form 8-K filings that 1,448 companies we cover made with the SEC in May 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Quantum X Labs announced on May 28, 2026 the launch of a 50+ qubit neutral-atom quantum computing platform and a goal of reaching thousands of qubits by the end of H1 2027. The filing is a product announcement and does not include financial results, guidance, or any financial figures for the company.
Platform launched May 28, 2026; described as having 50+ physical qubits and proprietary atom cooling technology
Company targets thousands of qubits by end of H1 2027, based partly on integrating a pending patented AI error correction decoder (US12294387B2)
Filing contains no revenue, profit, guidance, or dollar figures
Press release was furnished under Item 8.01 with Exhibit 99.1; signed by CEO Amihay Hadad on May 29, 2026
Whitehawk Therapeutics entered an option agreement with Hangzhou DAC Biotechnology for access to the CPT113 linker-payload for use in up to five additional antibody drug conjugate (ADC) programs. The filing does not disclose financial terms, and the company said Hangzhou DAC's DXC006, which uses CPT113, will present data at ASCO.
Option agreement gives Whitehawk access to CPT113 for up to five additional ADC programs; the filing gives no financial terms.
Whitehawk expects to submit IND applications for multiple new programs over the next 12-24 months.
Hangzhou DAC's DXC006 data were accepted for oral presentation at ASCO; the company's HWK-007 trial-in-progress poster is scheduled for May 30, 2026.
Phase 1 data for HWK-007 and HWK-016 are expected in the first half of 2027.
Vida Global announced that its tokenized equity, VIDAx, is now listed on Payward's xStocks framework and available for trading on the Kraken platform. The company says the listing lets eligible non-U.S. investors gain economic exposure to Vida shares through digital assets, and it follows the company's recent initial public offering on the NYSE American and NYSE Texas. The filing contains no financial results or guidance, and the company warns that tokenization may adversely affect liquidity and trading in its Class A common stock.
VIDAx tokenized equity is listed on xStocks and available for trading on the Kraken platform as of May 21, 2026.
The listing is aimed at eligible non-U.S. investors in more than 110 countries; the filing states that xStocks are not available in the U.S. or to U.S. persons.
The company cites its recent IPO on the NYSE American and NYSE Texas, and says xStocks has over $30 billion in combined transaction volume and more than 125,000 unique holders.
The filing lists risks, including possible effects on liquidity and trading in Vida's Class A common stock and uncertainty about the regulatory treatment of tokenized equity.
Wave Life Sciences released updated clinical data from the ongoing Phase 1b/2a RestorAATion-2 trial of WVE-006, an investigational RNA editing therapy for alpha-1 antitrypsin deficiency, and said it expects FDA feedback on a potential accelerated approval pathway in mid-2026. The data are early-stage, from small cohorts of eight patients each, and the company has not reported a trial outcome or regulatory decision, so the update's significance for shareholders depends on future regulatory and clinical results.
Single-dose 200 mg, 400 mg and 600 mg cohorts reached Z-AAT reductions of 47.3%, 49.7% and 59.1% from baseline, per the filing.
Multidose 200 mg biweekly cohort reached 70.5% Z-AAT reduction and total AAT of 11.9 µM; 400 mg monthly cohort reached 67.7% reduction and 13.6 µM.
Company expects FDA feedback on a potential accelerated approval pathway mid-2026 and data from the 600 mg multidose cohort in the second half of 2026.
All adverse events were mild to moderate, with no serious adverse events, according to the company.
CEL-SCI entered a strategic partnership, distribution, and revenue sharing agreement with Amarox covering regulatory affairs, marketing, and potential commercialization of Multikine for head and neck cancer in Saudi Arabia. The companies will share net revenue from Saudi sales 50%/50%, but the filing gives no dollar amounts, and Multikine is not yet approved for sale in any market.
Agreement announced May 11, 2026; 8-K dated May 14, 2026
Net revenue from Multikine sales in Saudi Arabia to be shared 50%/50%, with the revenue share tied to receipt of Breakthrough Medicine Designation from the SFDA
Amarox to act as local regulatory representative and to become exclusive commercial distributor upon SFDA approval, with an optional extension to GCC countries
On May 1, 2026, a Liberty Energy subsidiary signed two supply contracts with Bergen Engines AS for power generation equipment, with an aggregate purchase price of $505 million, for the company's prospective data center and other distributed power projects. Delivery is expected from the second half of 2027 through 2028, and Liberty must provide a parent guarantee for a specified portion of the price, so the deal commits significant capital ahead of those projects.
Two contracts priced at $224.4 million and $280.6 million, for an aggregate $505 million.
Contracts dated May 1, 2026; equipment delivery and takeover expected from the second half of 2027 through 2028.
Liberty must provide a parent guarantee for a specified portion of the contract price.
Termination for convenience requires Bergen's prior written agreement and certain payments to Bergen.
SAB Biotherapeutics entered a Master Manufacturing Services Agreement with Emergent BioSolutions Canada, effective April 28, 2026, under which Emergent will make SAB-142 clinical and commercial supply at its Canadian facility. The agreement sets a minimum aggregate spend of $36 million following any FDA approval of the product, and gives Emergent exclusive manufacturing rights during the term.
Agreement effective April 28, 2026, running five years from FDA approval of SAB-142
Minimum aggregate spend of $36 million following any FDA approval
Emergent has sole and exclusive right to manufacture the product; batch pricing to be set in a later amendment
Early termination by Emergent for insolvency, non-payment or material breach triggers payment of minimum annual spend for remaining years, less saved costs
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.